MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer-Reference-Cited by-同舟云学术

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Published:2014-11-26 Issue:7528 Volume:515 Page:558-562
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Powles Thomas,Eder Joseph Paul,Fine Gregg D.,Braiteh Fadi S.,Loriot Yohann,Cruz Cristina,Bellmunt Joaquim,Burris Howard A.,Petrylak Daniel P.,Teng Siew-leng,Shen Xiaodong,Boyd Zachary,Hegde Priti S.,Chen Daniel S.,Vogelzang Nicholas J.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature13904.pdf

Reference29 articles.

1. Choueiri, T. K. et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J. Clin. Oncol. 30, 507–512 (2012)

2. Bellmunt, J. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27, 4454–4461 (2009)

3. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014)

4. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013)

5. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013)

Cited by 2076 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced nanomaterials in prognostic implication of oncogenic role of CDCA7 and GALNT6 for bladder cancer treatment;Journal of Radiation Research and Applied Sciences;2024-12

2. Phenylboronic acid-functionalized biomaterials for improved cancer immunotherapy via sialic acid targeting;Advances in Colloid and Interface Science;2024-11

3. PD-L1 expression and tumor-infiltrating lymphocytes: Correlations and prognostic values in Chinese triple-negative breast cancer patients with different molecular subtyping;Pathology - Research and Practice;2024-10

4. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

5. CD68 positive and/or CD163 positive tumor-associated macrophages and PD-L1 expression in breast phyllodes tumor;Breast Cancer Research and Treatment;2024-09-06